The daily weight loss injection question, answered honestly

Step 1: understanding the once-weekly schedule (and why daily does not apply)

The idea of a daily weight loss injection crops up regularly in searches, but no such product holds a UK licence for weight management. The confusion often traces back to liraglutide (Saxenda), which was a once-daily injection licensed for obesity, or to short-acting insulin regimens sometimes used alongside older diabetes treatments. Neither is a current frontline option.

The two injections you will encounter in any legitimate UK weight-loss consultation are tirzepatide and semaglutide. Both are engineered to stay active in your body for roughly a week, which is why a single injection covers seven days. That longer half-life is a deliberate design feature: steadier hormone levels, one injection a week, and no need to remember a daily dose. The NHS medicines page for tirzepatide sets this out clearly.

One practical habit worth building: before each injection, hold the pen up to the light and check the solution looks clear and colourless. Cloudy or discoloured liquid is a reason to contact your prescriber before using it. Takes about five seconds.

If you would like to understand the broader range of options available, the weight-loss injection overview covers what is licensed and how each differs.

Step 2: what happens after the first injection

Both medicines start at a low dose. Tirzepatide begins at 2.5 mg per week; the first pen's job is to let your body adjust, not to produce dramatic results. Semaglutide begins at 0.25 mg. Your prescriber sets the titration schedule (typically moving up every four weeks) and no dose change happens without a clinical review.

The appetite shift usually becomes noticeable within the first two to four weeks. Most people find meals feel satisfying with less food, and the urge to snack between meals reduces. This is the gut-hormone mechanism at work: both medicines slow how quickly the stomach empties and increase the feeling of fullness after eating.

Gastrointestinal side effects are most common in the early weeks. Nausea, constipation, loose stools or belching can occur, particularly after a dose increase. They usually ease within days to a fortnight. Eating smaller portions, avoiding very fatty meals and staying well hydrated helps most people manage this phase. For a fuller picture of how weight-loss injections compare, including the side-effect profiles of each, there is a dedicated page on the site.

Women taking oral contraceptives and starting tirzepatide should use an additional non-oral method of contraception for the first four weeks of treatment and for four weeks after each dose increase, because absorption of the pill can be reduced. NHS England's guidance on weight-management injections covers this and other practical considerations, including what to tell your surgical team if you have a procedure planned.

Step 3: who these injections are licensed for

The licensed eligibility for private treatment follows the medicines' UK summaries of product characteristics. Adults with a BMI of 30 or above qualify, as do adults with a BMI of 27 or above if they have at least one weight-related health condition, for example, high blood pressure, type 2 diabetes, high cholesterol or obstructive sleep apnoea. Lower BMI thresholds can apply for some ethnic backgrounds under UK guidance.

BMI is a starting point, not the whole picture. A prescriber looks at your medical history, current medicines, and any conditions that might affect suitability before approving treatment. Anyone who is pregnant, breastfeeding or trying to conceive should not use these medicines; they are also not licensed for under-18s. Certain conditions (a personal or family history of medullary thyroid carcinoma, for instance, or a history of pancreatitis) require careful prescriber discussion before any GLP-1 medicine is considered. If you are comparing specific treatments, our page on weight loss injections starting with R explains how those options fit into the licensed landscape.

The question of how to get a weight-loss injection in the UK, including what the assessment process involves, is covered in full on a dedicated page.

Step 4: what to watch for and when to seek help

Most side effects are mild and transient, but a few warrant prompt medical attention. Severe stomach pain that spreads toward the back (with or without vomiting) can be a sign of pancreatitis, which is a known but uncommon side effect of GLP-1 medicines. The MHRA highlighted this in a Drug Safety Update in January 2026. Do not wait to see if it passes; get medical help the same day.

Other signs that need attention include symptoms of gallbladder problems (sudden pain in the upper right abdomen, particularly after eating), signs of dehydration from prolonged vomiting or diarrhoea, or any allergic reaction such as swelling of the face or throat. Patients can report suspected side effects directly to the MHRA at yellowcard.mhra.gov.uk.

For practical guidance on storing your pen, rotating injection sites and safe sharps disposal, the medication and injection guidance page has the detail. Needles should be changed with every injection; a sharps container keeps used needles disposed of safely at home.

If you are weighing up whether a once-weekly injection is the right approach for you, you may also find it helpful to review which weight loss injections offer the best value before starting your consultation. Our prescribers are available to help. Start your free consultation and a GPhC-registered prescriber will review your answers the same day.